top of page
Search
Michael Nguyen

Top 5 Liposomal Drugs on the Market

The development of liposomal drug formulations has transformed drug delivery by improving therapeutic efficacy, reducing toxicity, and enhancing the solubility of drugs to target specific tissues. Liposomes, which are spherical vesicles with lipid bilayers, encapsulate drugs, protecting them from degradation and allowing for controlled, targeted release. In this blog post, we’ll take a closer look at the top 5 liposomal drugs currently on the market, the lipid compositions that make them effective, and the year they were introduced, showcasing their long-standing impact on various therapeutic areas such as cancer treatment and antifungal therapies.


Pharmaceutical drugs

1. Doxil® (Liposomal Doxorubicin)

Therapeutic Use: Cancer (Ovarian cancer, Kaposi’s sarcoma, Multiple myeloma)


Brand Names: Doxil (USA), Caelyx (Europe and Canada)


Year Introduced: 1995


Lipid Composition:

  • Hydrogenated soy phosphatidylcholine (HSPC)

  • Cholesterol

  • Polyethylene glycol (PEG) 2000–distearoyl phosphatidylethanolamine (PEG-DSPE)


Doxil, introduced in 1995, is one of the most well-known liposomal formulations and contains doxorubicin, an anthracycline chemotherapy drug. Its lipid bilayer consists of HSPC, providing stability and rigidity, cholesterol, enhancing membrane integrity, and PEG-DSPE, a PEGylated lipid that allows the liposome to evade detection by the immune system. This stealth liposome formulation significantly prolongs the circulation time of the drug and enhances its accumulation in tumors through the enhanced permeability and retention (EPR) effect.


2. AmBisome® (Liposomal Amphotericin B)

Therapeutic Use: Fungal infections (Aspergillosis, Cryptococcosis)


Brand Name: AmBisome


Year Introduced: 1990


Lipid Composition:

  • Hydrogenated soy phosphatidylcholine (HSPC)

  • Cholesterol

  • Distearoylphosphatidylglycerol (DSPG)


Introduced in 1990, AmBisome is a liposomal formulation of amphotericin B, a potent antifungal agent used to treat severe fungal infections. The lipid composition includes HSPC, which stabilizes the lipid bilayer, cholesterol, which reinforces membrane integrity, and DSPG, a negatively charged phospholipid that enhances structural stability. AmBisome’s liposomal formulation reduces the renal toxicity associated with amphotericin B, allowing for safer administration and higher therapeutic doses.


3. Vyxeos® (Liposomal Daunorubicin and Cytarabine)

Therapeutic Use: Acute myeloid leukemia (AML)


Brand Name: Vyxeos


Year Introduced: 2017


Lipid Composition:

  • Distearoylphosphatidylcholine (DSPC)

  • Distearoylphosphatidylglycerol (DSPG)

  • Cholesterol


Vyxeos, introduced in 2017, is a liposomal combination of daunorubicin and cytarabine used for the treatment of acute myeloid leukemia (AML). The liposomal composition includes DSPC, which provides bilayer stability, cholesterol, which enhances membrane rigidity, and DSPS, a negatively charged phospholipid that contributes to structural stability and encapsulation efficiency. This drug is unique in its precise 1:5 molar ratio of daunorubicin to cytarabine, ensuring synergistic action in killing leukemia cells, while the liposomal delivery prolongs drug release for more effective treatment.


4. DepoCyt® (Liposomal Cytarabine)

Therapeutic Use: Lymphomatous meningitis


Brand Name: DepoCyt


Year Introduced: 1999


Lipid Composition:

  • Dioleoylphosphatidylcholine (DOPC)

  • Dipalmitoylphosphatidylglycerol (DPPG)

  • Triolein

  • Cholesterol


DepoCyt, introduced in 1999, is a liposomal formulation of cytarabine, specifically designed for the treatment of lymphomatous meningitis. Its lipid composition consists of DPPC, a saturated phospholipid that forms a stable bilayer, and cholesterol, which helps maintain membrane integrity. This formulation provides sustained release of cytarabine into the cerebrospinal fluid (CSF), reducing the need for frequent intrathecal injections and maintaining therapeutic drug levels for up to 14 days.


5. Onivyde® (Liposomal Irinotecan)

Therapeutic Use: Metastatic pancreatic cancer


Brand Name: Onivyde


Year Introduced: 2015


Lipid Composition:

  • Distearoylphosphatidylcholine (DSPC)

  • Cholesterol

  • Polyethylene glycol (PEG) 2000–distearoyl phosphatidylethanolamine (PEG-DSPE)


Introduced in 2015, Onivyde is a liposomal formulation of irinotecan, a topoisomerase inhibitor used for metastatic pancreatic cancer. Its lipid bilayer includes DSPC, which provides structural stability, cholesterol, which enhances membrane rigidity, and PEG-DSPE, which gives the liposomes a PEG coating to prolong circulation time. This liposomal design enables controlled, sustained release of irinotecan, improving drug accumulation in tumors and reducing the gastrointestinal side effects often seen with non-liposomal irinotecan.


The Impact of Liposomal Drug Delivery on Modern Medicine

The introduction of these liposomal drugs has revolutionized various therapeutic areas by improving the stability, targeting, and safety of drug delivery. The unique lipid compositions of these formulations offer several benefits, including:


  • Increased drug stability: Liposomes protect drugs from degradation in the bloodstream, increasing their bioavailability and therapeutic effectiveness.

  • Targeted delivery: Liposomes can accumulate in disease sites such as tumors, reducing off-target effects and enhancing drug efficacy.

  • Reduced toxicity: By encapsulating potentially toxic drugs, liposomes limit their interaction with healthy tissues, minimizing side effects.


The Future of Liposomal Drug Development

As research into lipid nanoparticle and liposome technologies advances, new formulations are being developed to address a broader range of diseases. The growing interest in personalized medicine, nanotechnology, and targeted delivery systems will likely drive the development of next-generation liposomal drugs, offering even greater precision and therapeutic benefits.


At Helix Biotech, we specialize in cutting-edge liposomal and lipid nanoparticle technologies, helping to advance the future of drug delivery. Whether your focus is on cancer therapeutics, gene therapy, or vaccines, our innovative solutions can help optimize drug delivery for improved patient outcomes. Contact us to learn how we can support your drug development needs.

Comments


bottom of page